Lung Cancer News and Research

Latest Lung Cancer News and Research

Dacomitinib ‘not superior’ to erlotinib in advanced NSCLC

Dacomitinib, an irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor, does not improve outcomes compared with the first-generation EGFR–TKI erlotinib in patients with advanced non-small-cell lung cancer, irrespective of their KRAS mutation status, finds the ARCHER 1009 study.

24 Nov 2014

Research shows that immune checkpoint inhibitors may work in glioblastoma, brain metastases

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

23 Nov 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

Accelerated treatment regimen feasible for advanced NSCLC

A treatment strategy designed to minimise the effects of accelerated repopulation using hypofractionated radiotherapy with chemotherapy is feasible for patients with stage III non-small-cell lung cancer, according to UK researchers.

21 Nov 2014

New course underlines the importance of early detection of lung cancer

In Japan, 40 percent of lung cancer cases are detected on early stages and treated with a high probability of remission; in the US 20 percent of cases have that possibility, while in Mexico, in the National Cancer Institute (INCan), only 1.2 percent of patients are diagnosed at an early stage.

21 Nov 2014

Researchers identify genetic signatures in melanoma tumors that predict response to immunotherapy

A team led by Ludwig and Memorial Sloan Kettering (MSK) researchers has published a landmark study on the genetic basis of response to a powerful cancer therapy known as immune checkpoint blockade.

21 Nov 2014

Biomarker-directed chemotherapy detrimental in NSCLC

Treating non-small-cell lung cancer patients with chemotherapy customised according to expression of BRCA1 and receptor-associated protein 80 does not improve progression-free survival compared with nonselected, cisplatin-based chemotherapy, show study findings.

19 Nov 2014

CT screening highly sensitive, specific for lung cancer detection

Low-dose computed tomography screening for lung cancer has high specificity and high sensitivity, with just a small number of interval cancers, finds an interim analysis of the NELSON trial.

19 Nov 2014

BerGenBio's BGB324 gets orphan-drug designation from FDA for AML treatment

BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukaemia (AML).

19 Nov 2014

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Prolonged passive smoking may increase lung cancer risk in women

Women who have never smoked but are exposed to smoking in the home for more than 30 years are at an increased risk of developing lung cancer compared with women without this passive smoking exposure, suggest researchers.

18 Nov 2014

Study finds significant disparities in lung cancer treatment based on race, insurance status

African Americans, Hispanics, and those who receive care at a community hospital are all significantly less likely than other patients to receive treatment for early stage non-small cell lung cancer, according to a report in the Journal of Thoracic Oncology.

18 Nov 2014